DA Davidson Trims USANA Health Sciences (NYSE:USNA) Target Price to $38.00

USANA Health Sciences (NYSE:USNA) had its price objective lowered by DA Davidson from $46.00 to $38.00 in a report released on Thursday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. DA Davidson also issued estimates for USANA Health Sciences’ Q3 2024 earnings at $0.46 EPS.

Separately, StockNews.com cut USANA Health Sciences from a strong-buy rating to a buy rating in a report on Wednesday.

USANA Health Sciences Trading Up 1.9 %

NYSE:USNA opened at $42.62 on Thursday. The business’s 50-day moving average is $46.01 and its 200 day moving average is $46.97. USANA Health Sciences has a 12 month low of $40.51 and a 12 month high of $68.00. The company has a market capitalization of $811.91 million, a P/E ratio of 13.28, a P/E/G ratio of 1.41 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. The firm had revenue of $212.87 million for the quarter, compared to the consensus estimate of $218.64 million. During the same quarter in the prior year, the company posted $0.89 earnings per share. On average, research analysts forecast that USANA Health Sciences will post 2.48 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other news, major shareholder Myron W. Wentz sold 13,496 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $45.03, for a total transaction of $607,724.88. Following the transaction, the insider now directly owns 7,864,345 shares in the company, valued at $354,131,455.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder Myron W. Wentz sold 2,202 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $47.79, for a total value of $105,233.58. Following the sale, the insider now directly owns 7,877,841 shares in the company, valued at approximately $376,482,021.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Myron W. Wentz sold 13,496 shares of USANA Health Sciences stock in a transaction on Friday, June 14th. The stock was sold at an average price of $45.03, for a total transaction of $607,724.88. Following the completion of the transaction, the insider now directly owns 7,864,345 shares in the company, valued at $354,131,455.35. The disclosure for this sale can be found here. Insiders sold 31,591 shares of company stock worth $1,458,098 over the last three months. 0.33% of the stock is owned by corporate insiders.

Institutional Trading of USANA Health Sciences

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of USANA Health Sciences by 2.5% during the third quarter. Vanguard Group Inc. now owns 1,567,182 shares of the company’s stock worth $91,853,000 after buying an additional 38,533 shares during the period. Pzena Investment Management LLC lifted its position in USANA Health Sciences by 3.1% during the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after acquiring an additional 23,729 shares during the period. Dimensional Fund Advisors LP lifted its position in USANA Health Sciences by 3.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock worth $36,323,000 after acquiring an additional 21,524 shares during the period. Charles Schwab Investment Management Inc. grew its stake in USANA Health Sciences by 4.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 222,423 shares of the company’s stock valued at $11,922,000 after purchasing an additional 8,536 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in shares of USANA Health Sciences by 2.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 111,492 shares of the company’s stock valued at $5,407,000 after purchasing an additional 2,820 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.